Less Ads, More Data, More Tools Register for FREE

US FDA Rejects New Drug Application For ViiV Healthcare HIV Treatment

Sat, 21st Dec 2019 11:40

(Alliance News) - ViiV Healthcare said Saturday it has received a complete response letter from the US Food & Drug Administration related to its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.

The FDA sends a complete response letter if it determines to not approve a new drug application in its current form.

ViiV, a joint venture of GlaxoSmithKline PLC, Pfizer Inc and Shionogi Ltd, said the reasons given by the FDA for its rejection relate to chemistry manufacturing and controls, rather than any safety issues. It said it will work with the US regulator to determine next steps for the application.

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IN BRIEF: GSK's ViiV Healthcare survey finds support for HIV regimen

IN BRIEF: GSK's ViiV Healthcare survey finds support for HIV regimen

Today 12:45

LONDON BROKER RATINGS: Shore Capital raises WPP to Buy from Hold

LONDON BROKER RATINGS: Shore Capital raises WPP to Buy from Hold

Today 09:32

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

27 Oct 21 14:37

TOP NEWS: GSK eyes steady annual payout after solid third quarter

TOP NEWS: GSK eyes steady annual payout after solid third quarter

27 Oct 21 12:41

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.